Imago BioSciences Future Growth
Future criteria checks 0/6
Imago BioSciences is forecast to grow earnings and revenue by 14% and 77.7% per annum respectively while EPS is expected to grow by 23.5% per annum.
Key information
14.0%
Earnings growth rate
23.5%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 77.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | n/a |
Recent future growth updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 11 | -122 | -115 | -92 | 5 |
| 12/31/2024 | N/A | -111 | -90 | -110 | 5 |
| 12/31/2023 | N/A | -88 | -73 | -83 | 6 |
| 12/31/2022 | N/A | -65 | -60 | N/A | 6 |
| 9/30/2022 | N/A | -62 | -52 | -52 | N/A |
| 6/30/2022 | N/A | -57 | -53 | -53 | N/A |
| 3/31/2022 | N/A | -52 | -44 | -44 | N/A |
| 12/31/2021 | N/A | -42 | -40 | -40 | N/A |
| 9/30/2021 | N/A | -33 | -31 | -31 | N/A |
| 6/30/2021 | N/A | -26 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -21 | -20 | -20 | N/A |
| 12/31/2020 | N/A | -18 | -17 | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMGO is forecast to have no revenue next year.
High Growth Revenue: IMGO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMGO's Return on Equity is forecast to be high in 3 years time